Document is current
Any future updates will be listed below
-
Authors
Vidal, Celia https://orcid.org/0000-0002-8760-6077
Bertelli, Fanny https://orcid.org/0000-0001-8701-180X
Mallet, Jean-Pierre https://orcid.org/0000-0001-7769-1717
Gilson, Raphael https://orcid.org/0009-0005-4332-7235
Borel, Jean-Christian https://orcid.org/0000-0003-4140-6210
Gagnadoux, Frédéric https://orcid.org/0000-0002-4231-5102
Bourdin, Arnaud https://orcid.org/0000-0002-4645-5209
Molinari, Nicolas https://orcid.org/0000-0002-1786-0088
Jaffuel, Dany https://orcid.org/0000-0002-6964-4766
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct03013283 at ClinicalTrials.govDocuments that mention this clinical trial
Mask side-effects are related to gender in long-term CPAP: results from the InterfaceVent real-life study
https://doi.org/10.1186/s12931-024-02965-1
Mask side-effects in long-term CPAP-patients impact adherence and sleepiness: the InterfaceVent real-life study
https://doi.org/10.1186/s12931-021-01618-x
- License Information
-
More Information
Article History
Received: 4 July 2024
Accepted: 31 August 2024
First Online: 6 September 2024
Declarations
:
: InterfaceVent is registered with ClinicalTrials.gov (NCT03013283). The protocol complied with the Declaration of Helsinki and was reviewed and approved by an independent ethics committee (Comité de Protection des Personnes Sud Mediterranée 1; reference number RO-2016/50). All participants had given their written informed consent.
: Not applicable.
: CV declares working for Adene home healthcare provider company. JPM declares grants/funds: Adene, Novartis, Chiesy, GSK, DPC-ORL; personal fees from Pulmon X. RG declares working for Adene home healthcare provider company. JCB declares consultant fees from AGIR à dom, a French Homecare provider. FG declares receipt of personal fees from AIR LIQUIDE SANTE, INSPIRE, BIOPROJET, RESMED and SEFAM; payment for presentations from BIOPROJET, CIDELEC, INSPIRE, RESMED, and SEFAM; non-financial support from ASTEN SANTE. AB declares grants/funds: Boehringer Ingelheim; personal fees: AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Novartis, Sanofi-Regeneron; clinical trial investigator: Acceleron, Actelion, Galapagos, Merck Sharpe & Dohme, Nuvaira, Pulmonx, United Therapeutic, Celltrion, Vertex. NM declares grants/funds: GlaxoSmithKline; personal fees: Sanofi-Regeneron. DJ reports personal fees from Lowenstein, Jazz, Bioprojet, Adene, Bastide, LVL, GSK, Astra, ALK, Bohringer Ingelheim, Sanofi, Philips Healthcare, and Resmed, personal fees and nonfinancial support from Sefam and Nomics, grants and personal fees from Novartis, outside the submitted work.
